August 3, 2014 | Israeli biotech company VBL Therapeutics announced the pricing of its NASDAQ IPO. The company will sell 5,400,000 shares at $12.00 per share for a gross total of $64.8 million. In addition, VBL Therapeutics will grant underwriters 30 days to purchase up to 810,000 additional shares at the same price in order to cover over-allotments. The shares began trading on NASDAQ on July 31, 2014 under the ticker symbol VBLX with the offering due to close on August 5, 2014. VBL Therapeutics was founded in 2000 in Tel Aviv, Israel and is currently working towards developing a cure for brain cancer, which it hopes to begin Phase III clinical trials on in 2015.